Skip to main content
PLOS Neglected Tropical Diseases logoLink to PLOS Neglected Tropical Diseases
. 2022 Apr 19;16(4):e0010275. doi: 10.1371/journal.pntd.0010275

A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru

Kathleen D Lynch 1,*, Sue Chen Apadinuwe 2, Stephen B Lambert 1,3, Tessa Hillgrove 4, Mitchell Starr 5, Beth Catlett 5, Robert S Ware 6, Anasaini Cama 4, Sara Webster 4, Emma M Harding-Esch 7, Ana Bakhtiari 8, Robert Butcher 7, Philip Cunningham 5, Diana Martin 9, Sarah Gwyn 9, Anthony W Solomon 10, Chandalene Garabwan 2, John M Kaldor 11, Susana Vaz Nery 11
Editor: Scott D Nash12
PMCID: PMC9017947  PMID: 35439248

Abstract

Background

The epidemiology of trachoma in several Pacific Islands differs from other endemic settings, in that there is a high prevalence of clinical signs of trachoma, particularly trachomatous inflammation—follicular (TF), but few cases of trichiasis and limited evidence of ocular chlamydial infection. This so-called “Pacific enigma” has led to uncertainty regarding the appropriate public health response. In 2019 alongside Nauru’s national trachoma population survey, we performed bacteriological and serological assessments of children to better understand the typology of trachoma and to determine whether there is a need for trachoma interventions.

Methods

We used two-stage cluster sampling, examining residents aged ≥1 year and collecting household-level water, sanitation, and hygiene (WASH) variables. Children aged 1–9 years provided conjunctival swabs and finger-prick dried blood spots to investigate the presence of Chlamydia trachomatis nucleic acid and anti-Pgp3 antibodies, respectively.

Principal Findings

In 818 participants aged 1–9 years, the age-adjusted TF prevalence was 21.8% (95% CI 15.2–26.2%); ocular C. trachomatis prevalence was 34.5% (95% CI 30.6–38.9), and anti-Pgp3 antibody prevalence was 32.1% (95% CI 28.4%–36.3%). The age- and gender-adjusted prevalence of trichiasis in ≥15-year-olds was 0.3% (95% CI 0.00–0.85), but no individual with trichiasis had trachomatous scarring (TS). Multivariable analysis showed an association between age and both TF (OR per year of age 1.3 [95% CI 1.2–1.4]) and anti-Pgp3 positivity (OR 1.2 [95% CI 1.2–1.3]). There were high rates of access to water and sanitation and no WASH variable was associated with the presence of TF.

Conclusions

TF, nucleic acid, and age-specific antibody prevalence collectively indicate that high levels of C. trachomatis transmission among children present a high risk of ocular damage due to trachoma. The absence of trichiasis with trachomatous scarring suggest a relatively recent increase in transmission intensity.

Author summary

In contrast to several neighbouring Pacific Island nations, Nauruan children are heavily affected by active trachoma and the cause is ocular infection with C. trachomatis. Comprehensive public health intervention to control trachoma in Nauru is required. The use of laboratory markers for current and previous C. trachomatis infection should be considered in baseline trachoma prevalence surveys as we approach global elimination of trachoma, and in settings with inconsistent findings during previous screening exercises.

Introduction

Trachoma is the leading infectious cause of blindness worldwide and was targeted in 1996 for elimination as a public health problem by the year 2020 [1,2]. The road map for neglected tropical diseases 2021–2030 has revised this target to 2030 [3]. Active trachoma is an inflammatory response to ocular infection with Chlamydia trachomatis. In trachoma-endemic areas, active trachoma, defined as trachomatous inflammation—follicular (TF) or trachomatous inflammation—intense (TI) in one or both eyes, is common among young children [4]. Repeated episodes of active trachoma cause chronic inflammation which can gradually lead to scarring of the inside of the eyelid (trachomatous scarring [TS]). Progressive conjunctival scarring can distort the eyelid margin and cause the eyelashes to turn inwards, touch the eyeball (trachomatous trichiasis [TT]), and painfully abrade the cornea [4]. Without intervention, the constant abrasion can lead to corneal opacity (CO) and irreversible blindness [5]. It is important to note that while there are other causes of trichiasis, TT is the result of progressive trachomatous scarring [6]. Trachoma elimination programmes employ the World Health Organization (WHO)-endorsed “SAFE” strategy: surgery for trichiasis, antibiotic treatment to clear infection, and facial cleanliness and environmental improvement to reduce transmission of ocular C. trachomatis [7]. These “AFE” interventions are recommended in evaluation units (EUs) where the prevalence of TF is ≥5% in children aged 1–9 years, and “S” is recommended where the prevalence of trichiasis is ≥0.2% in those aged ≥15 years (EUs are generally equivalent to a districts, which for trachoma elimination purposes WHO defines as “the normal administrative unit for health care management, consisting of a population unit between 100,000–250,000 persons”) [7,8].

Population-based surveys are undertaken to determine whether prevalence thresholds are exceeded in EUs where there has been recent evidence of trachoma. In 2007, a rapid assessment in Nauru found high levels of TF in children (20.7%–33.0%), but no trichiasis in older residents [9,10]. Rapid assessments use a “quick-and-epidemiologically-dirty” approach of convenience sampling for recruiting participants and are specifically designed to overestimate the percentage of children with TF. Whilst results could not be used as a prevalence estimate for programmatic planning, the findings did suggest that active trachoma may be a public health problem and provided justification for further investigation [11]. Subsequent population-based surveys in the neighbouring countries of Papua New Guinea (PNG), Solomon Islands, and Vanuatu had similar findings [1215]. Additionally, there was little indication in those countries of current C. trachomatis infection in children, based on polymerase chain reaction (PCR) detection on conjunctival swabs, or past infection based on antibodies to the C. trachomatis antigen Pgp3 [12,1517]. It was therefore hypothesised that in these three Melanesian nations, as-yet undetermined aetiologies may be responsible for much of the clinical syndrome that is phenotypically indistinguishable from TF, a phenomenon referred to as the “Pacific enigma” [16].

In July 2019, the Nauru Ministry of Health and Medical Services (MHMS) led a population-based trachoma survey using standard Tropical Data methods to assess the prevalence of clinical signs of trachoma and to collect data on household-level water, sanitation and hygiene (WASH) variables [18]. Given the findings of Nauru’s 2007 rapid assessment and the observations from neighbouring countries, the survey added a research component testing for evidence of current or past chlamydial infection in 1–9-year-olds. While a few previous studies have collected clinical, bacteriological, serological, and WASH variables, this study is the first nationwide trachoma survey in which all four types of data were generated simultaneously.

Methods

Ethics statement

Ethics approval for Tropical Data (https://www.tropicaldata.org/) support for the prevalence survey was provided by the London School of Hygiene & Tropical Medicine Ethics Committee (reference 16105). Ethics approval for the prevalence survey, collection, and testing of samples was granted by the University of New South Wales Human Research Ethics Committee (reference HC190442) and the MHMS, Nauru (17/06/2019). Verbal consent was obtained for clinical examination. A parent or guardian provided written consent for each child to provide biological samples. Direct contact with survey participants was undertaken entirely by MHMS staff. United States Centers for Disease Control and Prevention (CDC) staff did not interact with survey participants or have access to any identifying information. This report conforms with STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guidelines [19].

Trachoma survey design

The population-based prevalence survey was undertaken by the Nauru Ministry of Health with the support of The Fred Hollows Foundation using standard Tropical Data methods. Tropical Data builds on the systems and methods of the Global Trachoma Mapping Project [20,21]. The survey was restricted to Nauruan citizens, who comprise most of the population, and excluded foreign citizens working in Nauru and individuals seeking refugee status in Australia. We recruited survey participants using two-stage cluster sampling following standard Tropical Data methods, conforming to WHO recommendations [22,18]. Nauru’s estimated resident citizen population of 9,600 was surveyed as a single EU [2,10]. The sample size was calculated based on a targeted level of precision for estimation of a proportion, via the formula n = DEFF x p(1-p)/(2 x d/(1.96 x 2)2), with correction for a small, finite population [23]. Our estimated sample size requirement for 1–9-year-olds was 724, assuming a TF prevalence of 10% and a design effect of 2·65 to achieve a 95% confidence interval (CI) of width 6% [23]. It was increased by 25% to account for non-response, resulting in 905 children aged 1–9 years to be enumerated. In the first stage, 20 clusters with approximately equal population sizes were created using the fourteen administrative districts in Nauru plus six further subdivisions drawn within the three most populated districts [18]. In the second stage, 23 households were randomly sampled from each cluster using a pre-existing household list held by Nauru MHMS. Assuming a mean of two children aged 1–9 years per household, this sampling frame was expected to yield 920 resident 1–9-year-olds.

Teams conducted the survey in house-to-house visits in July 2019. Each team consisted of a minimum of four individuals: a team leader, certified grader, certified recorder, and a dried blood spot (DBS) specimen collector.

Household-level data collection

For consenting households, location (using GPS) was recorded and household-level WASH variables obtained from the self-nominated head of the household using standard Tropical Data methods described previously [22]. As per these methods, ten standard questions were asked about household level WASH access; data on handwashing facilities and access to toilet/latrine (if shared) were collected through head of household report [22]. Sanitation facilities were categorised as “improved” or “unimproved”, using definitions set by the WHO–UNICEF Joint Monitoring Programme (JMP) for Water Supply and Sanitation [24]. Handwashing facilities were only recorded if there was a latrine in the household, and were categorised as either “available with water and with soap”, “available with water but without soap”, or “no functioning handwashing facility available” [22]. All six recorders successfully passed the Tropical Data prevalence survey training programme which involves specific training and assessment of recorders [22]. All household- and individual-level data, including verbal consent, were captured electronically in real time using a purpose-built Secure Data Kit-based Android phone application, following standard Tropical Data procedures [22].

Clinical examination

Prior to conducting the survey, graders and recorders were required to pass internationally standardised training using the Tropical Data system [22]. In the week prior to the survey, field graders undertook a four-day training programme conducted by certified Tropical Data trainers using standardised training material. During the classroom session on examination techniques, trainees were taught how to recognise trichiasis (upper and lower eyelid) and TS. Consistent with the Tropical Data collection method, trainees were taught to recognise and collect data on only moderate or severe scarring as per the WHO simplified grading system definition of TS.

All residents of selected households ≥1 year of age for whom consent was given were examined for trachoma according to the WHO simplified trachoma grading scheme, using binocular 2.5× magnifying loupes and sunlight or a torch for illumination [5]. Participants found to have trichiasis (at least one eyelash touching the eyeball, or evidence of recent epilation of in-turned eyelashes) were further examined for TS and asked whether they had previously been offered surgery for trichiasis or advice to epilate, then referred to the national hospital for management. Participants with active trachoma were provided with two tubes of 1% tetracycline eye ointment.

Collection of conjunctival specimens and dried blood spots

The research component was undertaken alongside the national survey to collect information on laboratory correlates of clinical findings. Conjunctival specimens were collected by certified graders with assistance for specimen collection provided by the team leader and DBS specimen collector. The assistants were responsible for tube holding and specimen labelling. In the week prior to the survey, the team undertook training in conjunctival and DBS sample collection. This training incorporated infection control procedures to minimise the risk of specimen contamination in the field. For the first three days of fieldwork, specimen collection was supervised by a senior investigator.

Consent for participation in the research component of this work was sought from carers for individuals aged 1–9 years of age who were participating in the national survey. Conjunctival specimens for PCR testing were collected from the left (second-examined) eye from consented 1–9-year-olds following clinical examination. Using the Media Dual Swab Sample Packet (P/N: 05170516190, [Cobas, Roche Diagnostics, New Jersey, USA]), a sterile woven swab was passed three times (with a 120-degree turn between each pass) over the everted upper tarsal conjunctiva and then placed immediately into a Cobas PCR media tube without further contact. Control procedures were implemented to avoid cross contamination of specimens in the field. We took care to ensure the swab head was only in contact with an individual’s conjunctiva, and graders cleaned their hands with alcohol-based hand gel between each subject.

DBS for serological testing were collected via finger prick to absorb up to five spots (estimated 50 μL of whole blood per spot) onto Whatman 903 Protein Saver Cards (ThermoFischer Scientific Australia Pty Ltd, Victoria). The staff member collecting the DBS wore gloves, which were changed, and hand hygiene performed, after each participant. Swabs and DBS were carried with the teams for up to 8 hours and stored at room temperature (RT) at the end of each day. DBS cards were air-dried overnight, then each packed into an individual Whatman foil barrier bag (Bio-Strategy, VIC, Australia) containing two 1 g silica desiccant sachets (Desicco Pty Ltd NSW Australia). Swabs and DBS were stored from one to five weeks in Nauru at RT before being transported at ambient temperature to St Vincent’s Centre for Applied Medical Research, Sydney, Australia and stored at 2–8°C and −20°C, respectively, until laboratory testing. Detailed methods for PCR and serological testing are provided (see S1 Text).

PCR testing for ocular Chlamydia trachomatis

DNA was extracted from the swabs and tested for C. trachomatis via real-time PCR (Cobas 6800, Roche Diagnostics), using the Cobas C. trachomatis / Neisseria gonorrhoeae (CT/NG) dual assay; however, only the C. trachomatis results were evaluated as part of the study. Qualitative results were classified according to the manufacturer’s instructions.

We implemented rigorous control measures to prevent and identify contamination in the laboratory. There were separate and physically distinct areas in the laboratory designated for sample preparation, DNA extraction and PCR amplification. Each sample was uncapped in a biological safety hood class II, placed on board racks with the collection swab remaining inside the tube, then directly placed onboard the Roche COBAS 6800 instrument. Gloves were changed in between handling test reagents and samples. Testing was performed according to standard operating procedures (SOPs) and manufacturer’s Instructions for Use. The assay reagents include uracil-n-glycoslyase, which prevents carry over contamination onboard the instrument. Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme, which is included in the PCR master mix, during the first thermal cycling step.

Serological testing for anti-Pgp3 antibodies

Enzyme-linked immunosorbent assay

Samples eluted from DBS were tested by an enzyme-linked immunosorbent assay (ELISA) to detect the anti-C. trachomatis antibody anti-Pgp3 [25]. DBS samples and dried serum spots (DSS) were tested in duplicate. A blank spot was punched after each patient spot to reduce the risk of carry over contamination. The quality control criteria required to pass each testing plate followed CDC Instructions for Use. DSS positive for anti-Pgp3 antibodies across a range of responses, as well as negative human serum (NHS), were run on each plate [26]. Optical density was measured at 450nm on a Sunrise plate reader (Tecan Group Ltd, Switzerland). The average result from 6 blank wells was subtracted from each averaged absorbance value, and the result normalised against the mid-range positive control to account for plate-to-plate variation [25]. Plates were acceptable if results for 3 out of the 4 positive controls and the NHS control fell within pre-determined ranges (established during assay validation) and the positive controls were at least 50 times higher than background. Initially, 4 out of 21 plates (19%) did not meet quality control criteria provided by the CDC. The samples in these plates were re-punched, re-eluted and re-tested. Each repeat plate then passed quality control criteria. A finite mixture model was used to classify the samples as seropositive or seronegative based on normalized absorbance values. The threshold for seropositivity was determined to be 0.072 by taking the mean of the Gaussian distribution of the seronegative population plus four standard deviations above the seronegative population. Detailed methods for serological testing are provided (S1 Text).

Laboratory staff were blinded to all clinical results and samples were de-identified. The serological and molecular work was performed by two different groups in the laboratory and these groups were kept blinded to each other’s results.

Data analysis

Results of the laboratory testing were linked to the clinical results of the national survey and analysed together. TF prevalence was adjusted for age, and trichiasis prevalence for age and gender using standard methods for trachoma surveys, as previously described [20]. Prevalence (by PCR) and serology (by ELISA) were also adjusted for age. Data from Nauru’s 2011 census report were used as the reference dataset for the purposes of undertaking these adjustments [27]. Outcome variables were TF, C. trachomatis PCR positivity, and anti-Pgp3 seropositivity by ELISA. Logistic regression analyses were used to assess relationships between these outcomes and age, gender, and household-level WASH variables. First univariable analyses were undertaken, and then multivariable analyses with age, gender, time to get drinking water, time to get washing water, and latrine classification included as covariables. A post-hoc power calculation was undertaken to investigate the detectable alternative for the association between a two-category WASH variable and TF. For 818 children, assuming the variable had an 80:20 split (e.g. 654 in one category vs 164 in the other) and there was 25% TF in the reference WASH group, we had 80% power to detect a statistically significant difference if the percentage of TF in the comparator WASH group was 36% or greater. Cluster-robust variance estimates were calculated using sandwich estimators to account for the sampling scheme. Effect estimates are presented as crude odds ratios (ORs) and adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Average annual seroconversion rate and associated 95% CI were calculated using a generalised linear model with binomial family and identity link function. Statistical analyses were carried out using R (R Project for Statistical Computing, Vienna, Austria) and Stata v16.0 (StataCorp, College Station, TX, USA).

Results

A total of 459 households were visited and 2,515 people (53.3% female) examined across 20 survey clusters. 98 people declined to participate, and one adult could not be examined due to an ocular abnormality (Fig 1). Household-level WASH data were obtained for all households. Of 818 participating children aged 1–9 years, 96.2% (n = 787) resided in a household with access to an improved source of drinking water, 95.7% (n = 783) with access to an improved source of washing water, and 88.9% (n = 727) with access to an improved latrine.

Fig 1. Recruitment and results flow diagram, Nauru, July 2019.

Fig 1

Abbreviations: TF, trachomatous inflammation—follicular; TI, trachomatous inflammation—intense; TS, trachomatous scarring; PCR Ct, polymerase chain reaction Chlamydia trachomatis; ELISA, enzyme-linked immunosorbent assay; +ve, positive; -ve, negative. *This is a slight underestimation due to inconsistent recording of absenteeism in the first week of the survey. During this first week, 16% (124/764) of people were recorded as absent vs 27% (733/2707) across the remaining 3 weeks of the survey. Extrapolating the average level of absenteeism over the last three weeks to the first week, we expect an additional 82 individuals were absent.

Examination findings

Of the 818 children aged 1–9 years, 200 (24.4%) had TF and 9 (1.1%) had TI (Fig 1). The age-adjusted prevalence of TF in children was 21.8% (95% CI 15.2–26.2). Of 317 children aged 10–14 years, 35.6% (113) had TF. The prevalence of TF was 3% for 1-year-olds and increased with age to 38% in 9-year-olds (Fig 2), with a 1.28-fold increase in adjusted odds of having TF for each additional year of age within that age range (Table 1; 95% CI 1.18–1.40). Gender did not affect the odds of TF (Table 1; aOR 0.73, [95% CI 0.49–1.09]). TI prevalence increased with age, from 0.3% (1/346) of children <4 years, 1.7% (8/472) of children aged 5–9-years, to 35.6% (113/317) of those aged 10–14 years.

Fig 2. Prevalence of trachomatous inflammation—follicular, ocular Chlamydia trachomatis detection, and anti-Pgp3 antibodies in examined children aged 1–9 years in Nauru, July 2019.

Fig 2

Abbreviations: TF, trachomatous inflammation—follicular. Error bars showing 95% confidence intervals around survey prevalence estimate for each outcome.

Table 1. Factors associated with trachomatous inflammation—follicular (TF) in children aged 1–9 years, Nauru, July 2019 (n = 818).

Variable n TF+ve n (%) OR (95%CI); p-value aOR (95%CI); p-valuea
Age, increase per year
1–9 years 818 200 (24.5) 1.27 (1.17–1.37); <0.001 1.28 (1.181.40); <0.001
Gender
Male 426 112 (26.3) 1.0 (reference)
Female 392 88 (22.5) 0.81 (0.57–1.16); 0.25 0.73 (0.49–1.09); 0.13
Household source of water used for drinking
Improved 787 200 (25.4) 1.0 (reference) 1.0 (reference)
Unimproved 24 0 no events no events
Other 7 0 no events no events
Time to get drinking water
Water source in the yard 552 161 (29.2) 1.0 (reference) 1.0 (reference)
Travel required 266 39 (14.7) 0.42 (0.19–0.90); 0.03 0.47 (0.07–3.10); 0.43
Household source of water used for washing b
Improved 783 199 (25.4) 1.0 (reference) 1.0 (reference)
Unimproved 30 1 (3.3) 0.10 (0.01–1.46); 0.09 0.16 (0.01–1.20); 0.15
Time to get washing water
Water source in the yard 401 124 (30.9) 1.0 (reference) 1.0 (reference)
All face washing done at the source 152 36 (23.7) 0.69 (0.44–1.09); 0.12 0.76 (0.46–1.26); 0.29
Travel required 265 40 (15.1) 0.39 (0.18–0.87); 0.02 0.80 (0.12–5.28); 0.82
Where do adults in the household usually defecate?
Private latrine 788 189 (24.0) 1.0 (reference) 1.0 (reference)
Other 30 11 (36.7) 1.83 (0.88–3.81); 0.10 1.68 (0.88–3.23); 0.12
Household latrine
Improved 727 188 (25.9) 1.0 (reference) 1.0 (reference)
Unimproved 91 12 (13.2) 0.44 (0.12–1.55); 0.20 0.68 (0.20–2.31); 0.54
Is there a functioning handwashing facility available?
Handwashing available with water and with soap 713 173 (24.26) 1.0 (reference) 1.0 (reference)
Handwashing available with water but without soap 34 6 (17.65) 0.68 (0.32–1.39); 0.28 0.57 (0.22–1.48); 0.25
No functioning handwashing facility available 68 19 (27.94) 1.21 (0.70–2.10); 0.50 1.31 (0.72–2.40); 0.37

a Multivariable logistic regression model adjusted for age, gender, time to get drinking water, time to get washing water, latrine classification, and cluster;

b Five children lived in households with access that did not fit into the improved or unimproved category; bold denotes p<0.05.

There were six (0.4%) cases of trichiasis identified among 1,380 participants aged ≥15 years. All six cases were unilateral. Five of the cases were in individuals aged 15–39 years (60% male), and one in a female participant aged ≥40 years. There were two cases in children, a 9-year-old [male] and a 13-year-old [female] (Fig 1). Both cases were unilateral. The age- and gender-adjusted prevalence of trichiasis was 0.3% (95% CI 0.00–0.85). It was reported specifically by the graders that no individual with trichiasis had TS (Fig 1). In individuals aged ≥15 years, 5.1% (70/1380) had TF and 0.5% (7/1380) had TI.

Ocular C. trachomatis infection

PCR data on infection were missing for 4.6% of participants comprising 8 who refused, 14 had no swab collected and 16 for whom labelling errors prevented matching of PCR and clinical data. Of the 780 children for whom a swab was available, 272 (34.9%) were PCR-positive for C. trachomatis. The age-adjusted infection prevalence was 34.5% (95% CI 30.6–38.9). PCR positivity was more common in those with TF than those without (54.9% vs 28.3%; see Table 2 and Fig 3) but relatively stable by age (prevalence range: 30–41%) [S1 Table and Fig 2]). PCR positivity was associated with both TF (OR 2.65 [95% CI 1.71–3.55]) and seropositivity (OR 5.36 [95% CI 3.84–7.46]). Neither age (S1 Table; aOR 1.02 [95% CI 0.96–1.10]) nor gender (S1 Table; aOR 0.90 [95% CI 0.66–1.23]) affected the odds of infection.

Table 2. Comparison of detection of ocular Chlamydia trachomatis by polymerase chain reaction and anti-Pgp3 antibodies by enzyme-linked immunosorbent assay in 1–9-year-old children with and without trachomatous inflammation—follicular in either eye, Nauru, July 2019.

PCR ELISA
Total Positive Total Positive
Clinical examination findings TF 193 106 (54.9%) 193 101 (52.3%)
No TF 587 166 (28.3%) 599 175 (29.2%)

Abbreviations: PCR, polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay; TF, trachomatous inflammation—follicular.

Fig 3. Co-occurrence of clinical and laboratory findings in children aged 1–9 years in Nauru, July 2019.

Fig 3

Abbreviations: TF, trachomatous inflammation—follicular; ELISA, enzyme-linked immunosorbent assay; PCR, polymerase chain reaction.

Anti-Pgp3 serology

Serological data were missing for 3.2% of participants; 5 refused, 8 did not have a DBS collected, and labelling errors preventing matching of DBS cards and clinical data for 13 participants. No data are available on reason for refusal. DBS were available from 792/818 (96.8%) children aged 1–9 years (Fig 1). Overall, seroprevalence by ELISA was 34.8% (276/792); the age-adjusted prevalence was 32.1% (95% CI 28.4%–36.3%). For children with TF, 52.3% (101/193) were seropositive compared with 29.2% (175/599) without TF (Table 2). Seropositivity increased from 9.0% in those aged 1 year to 48% in those aged 9 years (Fig 2). The estimated seroconversion rate was 4.4% (95% CI 3.2–5.5%) per year of age, and the adjusted odds of being seropositive was 1.23-fold for each additional year of age in the 1–9-year-old range (S2 Table; aOR 1.23 [95% CI 1.15–1.32]). Seropositivity was associated with TF (OR 1.84 [95% CI 1.27–2.65]). The intensity of the ELISA response by year of age is shown in S1 Fig. Gender did not affect the odds of seropositivity (S2 Table, aOR 1.09 [95% CI 0.85–1.40]).

Water, sanitation, and hygiene access

There was no association between any WASH access variable and TF (Table 1). In multivariable analysis, when compared with access to an improved source of drinking water, access to an unimproved drinking source was associated with a decreased adjusted odds of PCR positivity (S1 Table; aOR 0.29 [95% CI 0.19–0.44]) and an increased adjusted odds of seropositivity (S2 Table; aOR 1.70 [95% CI 1.02–2.86]). Access to a functioning handwashing facility that lacked soap was associated with an increased adjusted odds of seropositivity (S2 Table; aOR 2.49 [95% CI 1.00–6.19]). No other WASH variable was found to be significant in the multivariable analysis.

Discussion

In the first national survey to simultaneously assess clinical, bacteriological, serological, and WASH markers of trachoma in children aged 1–9 years in Nauru, we found high levels of all three biological indicators defining transmission intensity of ocular C. trachomatis: PCR, serology, and TF. We also found strong correlations among these indicators. Amongst 1–9-year-olds, the prevalence of TF and serological positivity increased with age, while the prevalence of infection remained stable. Taken together, and in contrast to the situation in several neighbouring Melanesian nations, this study provides evidence that children in Nauru are heavily affected by active trachoma and that the cause is infection with C. trachomatis.

The prevalence of ocular C. trachomatis infection in Nauruan children at 34.9% is the highest reported in the Western Pacific Region, and its relationship with TF is consistent with those reported in Kiribati (the one Pacific country confirmed to date to have a high prevalence of ocular C. trachomatis infection) and trachoma-endemic areas of Sub-Saharan Africa [15,28,29]. In Kiribati, 81%–90.7% of PCR-positive children were seropositive [15,28]. By contrast, in Nauru, we found only 61.4% to be seropositive. While there are individuals who are PCR positive without TF or seropositivity for chlamydial antibodies, generally these outcomes co-occur within individuals. PCR positivity in the absence of TF or seropositivity was more common in younger children, possibly reflecting individuals with early infections who did not yet have inflammatory sequalae resulting in clinical signs and without an exposure level sufficient for seroconversion.

According to current WHO guidelines, the prevalence of TF (21.8% [95% CI 15.2–26.2%]) in Nauruan children constitutes a public health problem requiring implementation of the A, F and E components of the SAFE strategy. The trichiasis prevalence in adults >15 years of age exceeded the 0.2% threshold defined as that determining whether chronic complications of trachoma are a public health problem, but none of the individuals diagnosed with trichiasis had TS identified. TT is the result of progressive conjunctival scarring and in trachoma-endemic settings, most individuals with trichiasis present with moderate-severe conjunctival scarring [30]. Trichiasis without TS may be due to age-related changes, prior trauma, or inflammatory conditions [30]. Therefore, the absence of scarring in any of the cases suggests the trichiasis reported here may not be trachoma-related. This finding, in the context of highly prevalent TF in children, presents a perplexing picture of the public health threat posed by trachoma in Nauru. Furthermore, children had a low prevalence of TI, a manifestation of severe active trachoma which, if present on repeated occasions over prolonged periods of observation, is the best known predictor of TS in adults [31].

There are several possible explanations for this pattern of results. Trachoma may have been only recently introduced to children in Nauru and intense C. trachomatis transmission has not been occurring for sufficiently long to produce cicatricial disease in adults. However, the 2007 trachoma rapid assessment found that a high proportion of TF (20.7%–33.0%) in 1–9-year-old children [9]. If high ocular C. trachomatis transmission is a recent local phenomenon, the decline in national living standards over the past few decades, coincident with the decline in income from phosphate mining in Nauru, might be responsible. Although trichiasis was found, the definition of trichiasis includes recent epilation, which may be done for reasons other than corneal abrasion [30]. Another possibility is that some of the TF, C. trachomatis, and antibody positivity may be due to inclusion conjunctivitis, caused by ocular infection with urogenital strains of C. trachomatis. Inclusion conjunctivitis can have the same clinical manifestations as active trachoma and urogenital C. trachomatis has historically been reported to be highly prevalent in Nauru [32,33]. A recent report reported >20% of individuals tested were C. trachomatis positive. Further research investigating the contribution of specific C. trachomatis serovars to eye infection in Nauru via detailed molecular epidemiology of both ocular and genital C. trachomatis is required.

Access to sanitation has been associated with lower levels of both TF and C. trachomatis infection [34]. In comparison to neighbouring countries, Nauruan children have high levels of access to improved latrines (88.9%) [13,14,35]. This high level of sanitation coverage may explain the lack of association between latrine access and laboratory markers of chlamydial infection in this population. Despite the generally-held importance of household-level water access to trachoma elimination, the evidence from published research is inconsistent [34]. Almost all children in our study lived in households with access to improved sources of water for drinking (96.2%) and washing (95.7%), which may explain the lack of association of water variables and TF. Lack of soap at a functioning handwashing facility and an unimproved source of drinking water (not washing water) were associated with increased odds of anti-Pgp3 positivity, consistent with appropriate access to water and hygiene being beneficial. One unanticipated result was that an unimproved source of drinking water (not washing water) was associated with decreased odds of PCR positivity. It is possible that this result may be a type II error—finding an association where none exists or it may be due to an unmeasured confounding variable, such as socioeconomic status.

A number of limitations must be acknowledged. Firstly, PCR data on infection were missing for 4.6% of participants and serology missing for 3.2%. Second, as Pgp3 antibodies do not differentiate exposure to ocular from genital strains of chlamydia, seropositivity in an individual could reflect a range of potential exposures including trachoma, inclusion conjunctivitis, and perinatal transmission during childbirth [36,37]. An additional limitation shared by all standardised prevalence surveys using the Tropical Data method is that graders are trained to assess TS as “easily visible scarring” as per the WHO simplified grading system definition [22]. This encompasses moderate to severe scarring, and it is possible some mild scarring may be missed [38].

Finally, WASH variables collected as part of the Tropical Data methods were developed for settings where there is poor access to sanitation and water. In settings such as Nauru, where there is widespread access to safe household sanitation and water, the collection of additional variables associated with trachoma such as household crowding, and the frequency of face and hand washing should be considered.

As we approach global elimination more multi-modal, integrated screening and research, like this work, will be required. Given this, it would be ideal to have standardised methods for such work covering the capture, reporting, and interpretation of clinical, infection, and serosurvey data. Standardisation would allow for comparability across locations and provide a layer of quality control for reported results. Without such standardization, the assessment of scarring is difficult to interpret, and it is possible that cases of trichiasis are due to trachoma.

We set out to investigate the epidemiology of trachoma in Nauru. Our findings demonstrate the added value of using laboratory testing to provide richer insight. Clinical findings relating to trachoma across age-groups were not as expected, with prevalent childhood disease found in the absence of trichiasis plus TS in adults. While further work is required to understand this age-related discordance, our results show trachoma is rife in Nauruan children and suggest there has been a recent and substantial introduction of ocular C. trachomatis. The absence of TS and TT in adults further supports our conclusions. Based on these findings, Nauru implemented the SAFE strategy, including azithromycin mass drug administration for elimination of trachoma as a public health problem. Our approach of integrating collection of clinical, laboratory, and WASH data, and assessing all four variables in parallel, can maximise understanding of the current state of trachoma epidemiology in new or unusual settings. Similar integrated public health work and research will be required to drive progress towards the global elimination of trachoma as a public health problem.

Supporting information

S1 Fig. Absorbance for ELISA by year of age.

Each dot represents an individual participant. Red horizontal line indicates the cut-off for positivity.

(TIF)

S1 Table. Factors associated with Chlamydia trachomatis positive polymerase chain reaction (PCR) in children aged 1–9 years, Nauru, July 2019 (n = 780).

(DOCX)

S2 Table. Factors associated with Chlamydia trachomatis positive polymerase chain reaction (PCR) in children aged 1–9 years, Nauru, July 2019 (n = 780).

(DOCX)

S1 Text. Methods. Serological testing for anti-Pgp3 antibodies: Enzyme-linked immunosorbent assay.

(DOC)

Acknowledgments

We thank the residents of Nauru who gave their time to take part in this study. We also thank the field staff for their role in collecting data for the study. We thank Shanyko Benjamin for her role in laboratory support in Nauru. We thank Sarah Boyd of the International Trachoma Initiative, Cristina Jimenez of Sightsavers, Oliver Sokana of the Ministry of Health and Medical Services, Solomon Islands, and Sarity Dodson, Lizzie Jenkins, and Richard Le Mesurier from The Fred Hollows Foundation for their support of the study.

The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.

Data Availability

All relevant data are within the manuscript and its Supporting Information files

Funding Statement

This research was supported by The Fred Hollows Foundation using UK aid funding (primary grant held by Sightsavers International) this included salary support for AC and SVN. SC and CG received funds from The Fred Hollows Foundation for their role in implementing the trachoma survey. Core Tropical Data funding was provided by the International Trachoma Initiative; Sightsavers; and RTI International through the United States Agency for International Development (USAID) Act to End NTDs East program. AWS is a staff member of the World Health Organization. RB's salary is funded by The Fred Hollows Foundation (ref 1954-0). Staff from The Fred Hollows Foundation participated in the development of the study design, study preparation, staff training, and commenting on the draft manuscript.

References

  • 1.World Health Organization. Future Approaches to Trachoma Control–Report of a Global Scientific Meeting. Geneva: WHO; 1997. [Google Scholar]
  • 2.World Health Organization. Report of the 3rd Global Scientific Meeting on Trachoma Johns Hopkins University, Baltimore, MA 19–20 July 2010. Johns Hopkins University, Baltimore, USA: World Health Organization; 2010. [Google Scholar]
  • 3.World Health Organization. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. Geneva: World Health Organization, 2020. [Google Scholar]
  • 4.Mabey DCW, Solomon AW, Foster A. Trachoma. The Lancet. 2003;362(9379):223–9. doi: doi: 10.1016/s0140-6736(03)13914-1 [DOI] [PubMed] [Google Scholar]
  • 5.Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65(4):6. [PMC free article] [PubMed] [Google Scholar]
  • 6.Ramadhani AM, Derrick T, Holland MJ, Burton MJ. Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease. PLoS Negl Trop Dis. 2016;10(8):e0004859. Epub 2016/08/03. doi: doi: 10.1371/journal.pntd.0004859 ; PubMed Central PMCID: PMC4970760. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.World Health Organization. Validation of Elimination of Trachoma as a Public Health Problem. Geneva: World Health Organization, 2016 [Google Scholar]
  • 8.World Health Organization. WHO Alliance for the Global Elimination of Trachoma by 2020: progress report on elimination of trachoma, 2020. Wkly Epidemiol Rec. 2021;96(31):12. [Google Scholar]
  • 9.Mathew AA, Keeffe JE, Le Mesurier RT, Taylor HR. Trachoma in the Pacific Islands: evidence from Trachoma Rapid Assessment. Br J Ophthalmol. 2009;93(7):866. doi: doi: 10.1136/bjo.2008.151720 [DOI] [PubMed] [Google Scholar]
  • 10.Negrel A, Taylor HR, West S. Guidelines for rapid assessment for blinding trachoma. Geneva: World Health Organization, 2001 [Google Scholar]
  • 11.Solomon AW, Zondervan M, Kuper H, Buchan JC, Mabey DCW, Foster A. Trachoma control: a guide for programme managers. Geneva: World Health Organization, 2006. [Google Scholar]
  • 12.Macleod CK, Butcher R, Javati S, Gwyn S, Jonduo M, Abdad MY, et al. Trachoma, anti-Pgp3 serology and ocular Chlamydia trachomatis infection in Papua New Guinea. Clin Infect Dis. 2020. doi: doi: 10.1093/cid/ciaa042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sokana O, Macleod C, Jack K, Butcher R, Marks M, Willis R, et al. Mapping Trachoma in the Solomon Islands: Results of Three Baseline Population-Based Prevalence Surveys Conducted with the Global Trachoma Mapping Project. Ophthalmic Epidemiol. 2016;23(sup1):15–21. Epub 2016/12/13. doi: doi: 10.1080/09286586.2016.1238946 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Taleo F, Macleod CK, Marks M, Sokana O, Last A, Willis R, et al. Integrated Mapping of Yaws and Trachoma in the Five Northern-Most Provinces of Vanuatu.(Research Article)(Report)(Survey). PLoS Negl Trop Dis. 2017;11(1):e0005267. doi: doi: 10.1371/journal.pntd.0005267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Butcher R, Handley B, Garae M, Taoaba R, Pickering H, Bong A, et al. Ocular Chlamydia trachomatis infection, anti-Pgp3 antibodies and conjunctival scarring in Vanuatu and Tarawa, Kiribati before antibiotic treatment for trachoma. J Infect. 2020. doi: doi: 10.1016/j.jinf.2020.01.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Butcher RM, Sokana O, Jack K, Macleod CK, Marks ME, Kalae E, et al. Low Prevalence of Conjunctival Infection with Chlamydia trachomatis in a Treatment-Naive Trachoma-Endemic Region of the Solomon Islands. PLoS Negl Trop Dis. 2016;10(9):e0004863. Epub 2016/09/08. doi: doi: 10.1371/journal.pntd.0004863 ; PubMed Central PMCID: PMC5014345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Butcher R, Sokana O, Jack K, Sui L, Russell C, Last A, et al. Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis. Wellcome Open Res. 2018;3:14. doi: doi: 10.12688/wellcomeopenres.13423.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.World Health Organization Strategic and Technical Advisory Group for Neglected Tropical Diseases. Design parameters for population-based trachoma prevalence surveys. Geneva: World Health Organization; 2018. [Google Scholar]
  • 19.Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007;370(9596):1453–7. doi: doi: 10.1016/S0140-6736(07)61602-X [DOI] [PubMed] [Google Scholar]
  • 20.Solomon AW, Pavluck AL, Courtright P, Aboe A, Adamu L, Alemayehu W, et al. The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study. Ophthalmic Epidemiol. 2015;22(3):214–25. doi: doi: 10.3109/09286586.2015.1037401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Hooper PJ, Millar T, Rotondo LA, Solomon AW. Tropical Data: a new service for generating high quality epidemiological data. Community Eye Health. 2016;29(38). [Google Scholar]
  • 22.Courtright P, MacArthur C, Macleod C, Dejene M, Gass K, Harding-Esch E, et al. Tropical Data: training system for trachoma prevalence surveys. London: International Coalition for Trachoma Control; 2019. [Google Scholar]
  • 23.Kirkwood B. Essentials of Medical Statistics. Oxford, United Kingdom: John Wiley and Sons Ltd; 1988. 246 p. [Google Scholar]
  • 24.World Health Organization, United Nations International Children’s Emergency Fund. JMP Methodology: 2017 Update & SDG Baselines. 2018.
  • 25.Migchelsen S, Martin D, Southisombath K, Turyaguma P, Heggen A, Rubangakene P, et al. Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies. PLoS Negl Trop Dis. 2017. doi: 10.1371/journal.pntd.0005230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Gwyn S, Cooley G, Goodhew B, Kohlhoff S, Banniettis N, Wiegand R, et al. Comparison of Platforms for Testing Antibody Responses against the Chlamydia trachomatis Antigen Pgp3. Am J Trop Med Hyg. 2017;97(6):1662–8. doi: doi: 10.4269/ajtmh.17-0292 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nauru Government. Republic of Nauru national report on population and housing: census 2011. In: Nauru Bureau of Statistics, editor. https://www.spc.int/nmdi/nmdi_documents/2011_NAURU_CENSUS_REPORT.pdf2012. p. 195.
  • 28.Cama A, Muller A, Taoaba R, Butcher RMR, Itibita I, Migchelsen SJ, et al. Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati. PLoS Negl Trop Dis. 2017;11(9):e0005863. doi: doi: 10.1371/journal.pntd.0005863 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ramadhani AM, Derrick T, Macleod D, Holland MJ, Burton MJ. The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment.(Research Article)(Report). PLoS Negl Trop Dis. 2016;10(10):e0005080. doi: doi: 10.1371/journal.pntd.0005080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Rajak SN, Habtamu E, Weiss HA, Bedri A, Gebre T, Bailey RL, et al. The clinical phenotype of trachomatous trichiasis in Ethiopia: not all trichiasis is due to entropion. Invest Ophthalmol Vis Sci. 2011;52(11):7974–80. doi: doi: 10.1167/iovs.11-7880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.West SK, Muoz B, Mkocha H, Hsieh Y- H, Lynch MC. Progression of active trachoma to scarring in a cohort of Tanzanian children. Opthalmic Epidemiology. 2001;8(2–3):137–44. doi: doi: 10.1076/opep.8.2.137.4158 [DOI] [PubMed] [Google Scholar]
  • 32.Darougar S, Forsey T, Jones BR, Allami J, Houshmand A. Isolation of Chlamydia trachomatis from eye secretion (tears). Br J Ophthalmol. 1979;63(4):256–8. doi: doi: 10.1136/bjo.63.4.256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Ministry of Health of Nauru. Nauru Global AIDS Progress Report. 2016.
  • 34.Garn JV, Boisson S, Willis R, Bakhtiari A, Al-Khatib T, Amer K, et al. Sanitation and water supply coverage thresholds associated with active trachoma: Modeling cross-sectional data from 13 countries. PLoS Negl Trop Dis. 2018;12(1):e0006110-e. doi: doi: 10.1371/journal.pntd.0006110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ko R, Macleod C, Pahau D, Sokana O, Keys D, Burnett A, et al. Population-Based Trachoma Mapping in Six Evaluation Units of Papua New Guinea. Ophthalmic Epidemiol. 2016;23(sup1):22–31. doi: doi: 10.1080/09286586.2016.1235715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Schachter J, Grossman M, Sweet RL, Holt J, Jordan C, Bishop E. Prospective Study of Perinatal Transmission of Chlamydia trachomatis. JAMA. 1986;255(24):3374–7. doi: doi: 10.1001/jama.1986.03370240044034 [DOI] [PubMed] [Google Scholar]
  • 37.Migchelsen SJ, Sepulveda N, Martin DL, Cooley G, Gwyn S, Pickering H, et al. Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia. Sci Rep. 2017;7(1):15040. Epub 2017/11/10. doi: doi: 10.1038/s41598-017-15056-7 ; PubMed Central PMCID: PMC5678181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Astale T, Ebert CD, Nute AW, Zerihun M, Gessese D, Melak B, et al. The population-based prevalence of trachomatous scarring in a trachoma hyperendemic setting: results from 152 impact surveys in Amhara, Ethiopia. BMC Ophthalmol. 2021;21(1):213-. doi: doi: 10.1186/s12886-021-01972-w [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0010275.r001

Decision Letter 0

Michael Marks, Scott D Nash

1 Oct 2021

Dear Kathleen Lynch,

Thank you very much for submitting your manuscript "A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

  

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Scott D Nash

Guest Editor

PLOS Neglected Tropical Diseases

Michael Marks

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

This manuscript describes a detailed trachoma survey in Nauru. A few minor comments:

-The LFA assay is first noted in the Data analysis section, and then later in the Results. Please include information on this assay either in the methods or in the supplemental material.

-The prevalence of TI is first mentioned in the Discussion. Please include this point in the Results section to help the reader.

-Please make sure C. trachomatis is italicized appropriately throughout the manuscript, including the abstract.

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: This was no doubt a well planned study and expensive to undertake. I don't understand why the WHO Simplified grading was used instead of a finer grading of active trachoma. If one is going to spend the time, the effort and the money to do PCR and serology, one would expect to at least grade trachoma with some precision. The Simplified grading scheme was designed for health workers to assess the public health impact of trachoma. To determine if the SAFE strategy or even MDA was needed in Nauru on could always also categorise the findings from a more specific gradings into TF or TT. It is highly likely that many children will have had F1 or F2 but not sufficient large follicles to be TF and equally many will have had C1 or C2 without reaching the threshold for TS!!

For a very detailed research study like this, one wonders why were photos of the tarsal plate not taken?

Again if the challenge was to try to infer something about the history or trachoma in Nauru more detail should be provided about the findings in each of the age groups over 9 years of age.

Although WASH data were collected for the households, no data are presented for facial cleanliness. This is in many ways the key indicator for personal hygiene. it is very surprising that this was left out.

When a case was found the child was given 2 tubes of tetracycline ointment. Why wasn't the household treated with azithromycin or was MDA done later?

Reviewer #2: (No Response)

Reviewer #3: Generally, the methods are described adequately, with the exception of methods to detect and manage contamination in the field and laboratory. These need to be expanded as described below

while the sample size was done to provide estimates of TF, since further analyses were done with WASH variables, the authors should provide calculations of power to detect differences when rates of access to some variables were so high

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: The data for adults should be presented appropriately broken down by age and gender.

The finding of one child under 10 with trichiasis is most unusual. This should be further explained as should the one case in those 10 to 15.

Reviewer #2: (No Response)

Reviewer #3: Table S1 should really be a table in the text itself

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: The rates of TF are low in the children less that 5 years, although the PCR rates are high. Is this because these children had active trachoma but less that the 5 follicles 0.5mm needed to be called TF?

With the suggestion the "TS may not have been graded accurately" and the lack of a more detailed grading of tarsal scarring or photo documentation, these findings are really just speculation.

The "trachoma paradox" in the Pacific is a somewhat fanciful construct. It does not take into consideration that the rates and severity of trachoma can change over time. With population growth and increased crowding, without commensurate improvements in personal and community hygiene, trachoma can become more common and more severe.

The term "paratrachoma" was used by some for a while in the 1960s, as a term for chlamydial conjunctive infection that after a period of time resolved on its own without blinding sequelae. It seems this term has been misinterpreted. Paratrachoma was another name for "inclusion conjunctivitis". It could be caused by a single infection with any serovar. It was commonly seen with the genital strains because because there was usually only a single infective episode. The person was not subjected to the repeated episodes of reinfection required fro the development of "trachoma". The suggestion that these children, 24% of them, all had an almost simultaneous single infection seems just wrong.

Reviewer #2: (No Response)

Reviewer #3: The limitations in the discussion need to be expanded, and the conclusion around infection need to be re thought if there is in fact evidence of contamination.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: Data for the adults needs to be presented more fully.

If photos were taken of clean face data collected they need to be presented.

Reviewer #2: (No Response)

Reviewer #3: There needs to be much more clarity on how the potential for contamination of samples was addressed in the field and in the lab. This is a major concern.

The authors also have to use TT in place of trichasis in several places, and by the results, they have to decide if they believe the TS data and what they found is not TT , or they don't and it is TT. The ramifications of either decision deserve further discussion.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: This is an experienced group, working on a small island, using some very sophisticated tests. However, they seem to have omitted the key elements required for the sort of study they are trying to present. If the the study were just a rapid assessment of trachoma, the PCR and serology are not needed. If this were an attempt to study the dynamics and kinetics of trachoma in Nauru, then they must use a finer grading system for trachoma and also present the data for the adults. If this were an attempt to look at the reasons trachoma might occur in Nauru, then in addition to the WASH factors, they must include facial cleanliness.

Reviewer #2: This is a well written an interesting study evaluating active trachoma, C. trachomatis, and serologic markers of C. trachomatis in Nauru. These data are interesting given the ongoing investigation of the “Pacific enigma”.

1. Were WASH facilities observed or data collected by participant report only? (These may appear in the cited paper but a sentence so that readers don’t have to refer to the cited paper would be helpful).

2. How many household WASH indicators were entered into stepwise models and were these variables possibly collinear? Stepwise regression models can be a little problematic in that they tend to overfit, with over-estimated effect sizes and under-estimated variances. Depending on how many candidate variables are included (which isn’t clear from the methods), could all of the candidate variables be included (assuming there aren’t major problems with collinearity)? Looking at the supplemental tables, it’s a little unclear if a stepwise procedure was actually used (looks like all candidate variables are in the models), so if no stepwise procedure was used I would update the methods accordingly.

3. Page 20, Line 347 – could the authors speculate as to why they’re observing a lower seropositivity among PCR positives in their study versus Kiribati?

4. Are there plans for antibiotic-based intervention for trachoma in Nauru (or, do the authors believe its warranted given these results)?

5. The relationship between WASH and trachoma variables could very well be due to unmeasured confounding, for example, by SES (in previous studies and in this one). It would be worth mentioning that cross-sectional associations shouldn’t infer causality and that there’s high risk of unmeasured confounding here. I think further survey work won’t really help us understand these questions, but randomized controlled trials might.

Reviewer #3: The manuscript adds data on trachoma in the Pacific Islands, and supports a more recent introduction of trachoma. My main concern is the possible presence of contamination in the infection results. Control measures in the filed or the lab are not described, and the results are strongly suggestive of a problem. That said, there needs to be infection in order to have contamination, so the likelihood that the infection data supports the finding of TF is strong. Nevertheless, this concern is given scant attention and needs to be addressed as described below

Abstract: the conclusion that “the absence of trichiasis with trachomatous scarring suggest a relatively recent increase in transmission intensity” is liable to be confusing to readers who are unfamiliar with the distinction between trachomatous trichiasis (TT) and trichiasis due to other causes, especially as the abstract presented results on the prevalence of trichiasis as though it was TT, and thus were given importance like the rest of the trachoma related data. Either the authors believe their TS data and this is likely not trachomatous trichiasis, or they do not and the prevalence can be reported as TT. The sentence does need to be modified. Perhaps if that sentence on prevalence of trichiasis were deleted from the abstract, and a statement that although trichiasis was found, the absence of scarring in any of the cases suggested it may not be due to trachoma. Then the conclusion would make more sense to the reader, if that is what the authors think.

Abstract: The Abstract needs to reflect the high rate of access to water and sanitation, then state no relationship was found with the presence of TF, so the reader quickly has an understanding of why that might be.

Line 89-90:Introduction: Again, the description of the pathogenesis of trichiasis is really for trachomatous trichiasis and should be labeled as such, not just trichiasis. Here would be an excellent place to indicate that while there are other causes of trichiasis, TT is the result of progressive trachomatous scarring.

Line 96: please change to “where prevalence of trachomatous trichiasis (TT) is >0.2%

Line 124: I believe that one of the surveys in Peru collected all the indicators as well-if the authors mean the first national survey, because the entire nation was done in one survey, then they are likely right as very few countries are that small.

Line 194: Given that the infection rate is so high, higher than the rate of TF, and does not go up with age, suggests that there may have been field and/or lab contamination. Can the control procedures to avoid field contamination be described? Were control swabs taken to check for field contamination? The high rate of infection positivity in those without disease is further concerning.

Line 223: how many plates were not acceptable. Were the samples re run?

Results and Figure 3. The data provide further supportive evidence of contamination. When fully 61% of positive test of infection is not accompanied by presence of disease, and half of those don’t even have positive serology, then one must investigate if contamination is an issue. We expect no disease but positive serology, given the cumulative nature of seropositivity-but that does not hold for infection

Line 389. Discussion: The authors need to consider that the results reflect a problem with the infection data-if indeed there was contamination, and several infection negative children were misclassified, this could produce the result found.

Line 398: the limitation section needs more serious thought. How about the absence of data on other factors that may reflect transmission environment, like household crowding? Other WASH indicators may have found an association like frequency of face or handwashing-hence the need to put table S1 in the paper and not in the supplemental tables. Although mentioned briefly, the high proportion of children with very good access to water and improved latrines does limit the ability to find any association, and the authors could provide power calculations to back that up. As for scarring, are there any images of the eyelids in adults that could be checked for presence of scarring. Scarring severe enough to produce TT is usually easily visible, so that could be backed up with images.

I find that Table S1 is more valuable than table 1, which can be easily summarized in the text, if only a few tables/figures are allowed. Table S1 provides more detail on the WASH variables, and also shows the problem of trying to find associations when there is scant dispersion.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0010275.r003

Decision Letter 1

Michael Marks, Scott D Nash

12 Jan 2022

Dear Kathleen Lynch,

Thank you very much for submitting your manuscript "A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Thank you to the authors for their thoughtful responses to the Reviewers' first round of comments. After further review, there remain 2 main issues that are concerning the reviewers.

For the first point, about the possibility of contamination in the samples, the authors have been very clear in their explanation of contamination control during the laboratory work. For the possibility of field contamination, are the authors able to provide any more information as to how the samples were collected in the field, for example the training involved, and whether or not grader worked alone to do the work or whether there was assistance, possibly a "tube holder" if you will? The authors are recommended to either include the point in the limitation section as the reviewer suggests, or further evaluate/discuss the presence of high infection across the age groups, even among those without clinical signs or serological responses and what that may mean in this population.

For the second point on the grading of TS, while they may not have "standardized" their TS grading, the authors are clear in their responses that they trust their graders. To increase trust among readers, the authors need to further detail the Tropical Data training that they used In Nauru as it relates to training on TT and TS specifically, including what classroom and/or field training went into the assessment of TT and TS. The authors are further welcome to recommend whether they think enhanced training and/or data collection would have been useful.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Scott D Nash

Guest Editor

PLOS Neglected Tropical Diseases

Michael Marks

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Thank you to the authors for their thoughtful responses to the Reviewers' first round of comments. After further review, there remain 2 main issues that are concerning the reviewers.

For the first point, about the possibility of contamination in the samples, the authors have been very clear in their explanation of contamination control during the laboratory work. For the possibility of field contamination, are the authors able to provide any more information as to how the samples were collected in the field, for example the training involved, and whether or not grader worked alone to do the work or whether there was assistance, possibly a "tube holder" if you will? The authors are recommended to either include the point in the limitation section as the reviewer suggests, or further evaluate/discuss the presence of high infection across the age groups, even among those without clinical signs for or serological responses and what that may mean in this population.

For the second point on the grading of TS, while they may not have "standardized" their TS grading, the authors are clear in their responses that they trust their graders. To increase trust among readers, the authors need to further detail the Tropical Data training that they used as it relates to training on TT and TS specifically, including what classroom and/or field training went into the assessment of TT and TS. The authors are further welcome to recommend whether they think enhanced training and/or data collection would have been useful.

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #2: (No Response)

Reviewer #3: the authors have responded to reviewer concerns

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #2: (No Response)

Reviewer #3: the autbors have responded to reviewer concerns

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #2: (No Response)

Reviewer #3: The authors have gone to great lengths to assure us of the absence of contamination in acquisition of the ocular swab and in laboratory processing. They have also referenced the one article by Solomon et al, where very high rates of PCR positivity were seen in three settings , in some cases greater than the rates of TF. this article was published in 2003 before the necessity of careful standardization in both laboratory and in the field was appreciated. While the collection of air swabs is not a perfect way to guarantee absence of contamination, it is one way to provide some assurances there was none. To cite detailed protocols is helpful but without some data to provide reassurances of absence of contamination, the possibility must be entertained, if at least in limitations. it is difficult to see data where there is no age effect in infection, yet an age effect in seropositivity, and in disease. I believe the authors cannot exclude the possibility of field contamination in their data, despite the protocol, and that mention of this possibility must be present in the limitations. With all we have learned in the 19 years years since the cited study, it is difficult to believe that so many young children had infection without either disease or without being seropositive.

Secondly, the absence of standardization of scarring in grading is a concern when it is to be used to decide if trichiasis is due to trachoma. The authors have decided these cases are not due to trachoma. The limitations state that the graders may have missed mild scarring but without standardization, we do not know if they could have missed moderate scarring. The limitations should say that without standardization, the assessment of scarring is difficult to interpret and it is possible these are due to trachoma. The authors have gone to great lengths to assure us of the absence of contamination in acquisition of the ocular swab and in laboratory processing. They have also referenced the one article by Solomon et al, where very high rates of PCR positivity were seen in three settings , in some cases greater than the rates of TF. this article was published in 2003 before the necessity of careful standardization in both laboratory and in the field was appreciated. While the collection of air swabs is not a perfect way to guarantee absence of contamination, it is one way to provide some assurances there was none. To cite detailed protocols is helpful but without some data to provide reassurances of absence of contamination, the possibility must be entertained, if at least in limitations. it is difficult to see data where there is no age effect in infection, yet an age effect in seropositivity, and in disease. I believe the authors cannot exclude the possibility of field contamination in their data, despite the protocol, and that mention of this possibility must be present in the limitations. With all we have learned in the 19 years years since the cited study, it is difficult to believe that so many young children had infection without either disease or without being seropositive.

Secondly, the absence of standardization of scarring in grading is a concern when it is to be used to decide if trichiasis is due to trachoma. The authors have decided these cases are not due to trachoma. The limitations state that the graders may have missed mild scarring but without standardization, we do not know if they could have missed moderate scarring. The limitations should say that without standardization, the assessment of scarring is difficult to interpret and it is possible these are due to trachoma.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #2: (No Response)

Reviewer #3: (No Response)

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article's retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0010275.r005

Decision Letter 2

Michael Marks, Scott D Nash

24 Feb 2022

Dear Ms. Lynch,

We are pleased to inform you that your manuscript 'A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Scott D Nash

Guest Editor

PLOS Neglected Tropical Diseases

Michael Marks

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

PLoS Negl Trop Dis. doi: 10.1371/journal.pntd.0010275.r006

Acceptance letter

Michael Marks, Scott D Nash

4 Apr 2022

Dear Ms Lynch,

We are delighted to inform you that your manuscript, "A national survey integrating clinical, laboratory, and WASH data to determine the typology of trachoma in Nauru," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Absorbance for ELISA by year of age.

    Each dot represents an individual participant. Red horizontal line indicates the cut-off for positivity.

    (TIF)

    S1 Table. Factors associated with Chlamydia trachomatis positive polymerase chain reaction (PCR) in children aged 1–9 years, Nauru, July 2019 (n = 780).

    (DOCX)

    S2 Table. Factors associated with Chlamydia trachomatis positive polymerase chain reaction (PCR) in children aged 1–9 years, Nauru, July 2019 (n = 780).

    (DOCX)

    S1 Text. Methods. Serological testing for anti-Pgp3 antibodies: Enzyme-linked immunosorbent assay.

    (DOC)

    Attachment

    Submitted filename: Response to reviewers.docx

    Attachment

    Submitted filename: Response to reviewers_08FEB22.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files


    Articles from PLoS Neglected Tropical Diseases are provided here courtesy of PLOS

    RESOURCES